Oral propranolol for infantile hemangiomas: a prospective study on the role of 48-hour Holter monitoring in additional safety assessment

References

• Marlen J, Mulliken J. Current management of hemangiomas and vascular malformations. Clin Plast Surg. 2005;32:99–116.
   PubMed Web of Science ®Google Scholar
• Drolet B, Esterly N, Frieden I. Hemangiomas in children. N Engl J Med. 1999;341:173–81.
   PubMed Web of Science ®Google Scholar
• Léauté-Labrèze C, Dumas de la Roque E, Hubiche T, et al. Propranolol for severe hemangiomas of infancy. N Engl J Med. 2008;358:2649–51.
   PubMed Web of Science ®Google Scholar
• Léauté-Labrèze C. [Propranolol in infantile hemangiomas]. Arch Pediatr. 2015;22:452–55.
   PubMed Web of Science ®Google Scholar
• Rössler J, Haubold M, Gilsbach R, et al. β1-Adrenoceptor mRNA level reveals distinctions between infantile hemangioma and vascular malformations. Pediatr Res. 2013;73:409–13.
   PubMed Web of Science ®Google Scholar
• Stiles J, Amaya C, Pham R, et al. Propranolol treatment of infantile hemangioma endothelial cells: a molecular analysis. Exp Ther Med. 2012;4:594–604.
   PubMed Web of Science ®Google Scholar
• Lee D, Boscolo E, Durham JT, et al. Propranolol targets the contractility of infantile haemangioma-derived pericytes. Br J Dermatol. 2014;171:1129–37.
   PubMed Web of Science ®Google Scholar
• Ji Y, Chen S, Li K, et al. The role of β-adrenergic receptor signaling in the proliferation of hemangioma-derived endothelial cells. Cell Div. 2013;8:1.
   PubMed Web of Science ®Google Scholar
• Blanke K, Dähnert I, Salameh A. Role of connexins in infantile hemangiomas. Front Pharmacol. 2013;4:41.
   PubMed Web of Science ®Google Scholar
• Zhang L, Mai HM, Zheng J, et al. Propranolol inhibits angiogenesis via down-regulating the expression of vascular endothelial growth factor in hemangioma derived stem cell. Int J Clin Exp Pathol. 2014;7:48–55.
   PubMed Web of Science ®Google Scholar
• Wong A, Hardy KL, Kitajewski AM, et al. Propranolol accelerates adipogenesis in hemangioma stem cells and causes apoptosis of hemangioma endothelial cells. Plast Reconstr Surg. 2012;130:1012–21.
   PubMed Web of Science ®Google Scholar
• Zegbi-Trueba MS, Abarzúa-Araya A, Silva-Valenzuela S, et al. Oral propranolol for treating infantile hemangiomas: a case series of 57 patients. Actas Dermosifiliogr. 2012;03:708–17.
   Google Scholar
• El Ezzi O, Hohlfeld J, de Buys Roessingh A. Propranolol in infantile haemangioma: simplifying pretreatment monitoring. Swiss Med Wkly. 2014;144:w13943.
   PubMed Web of Science ®Google Scholar
• Ma X, Zhao T, Xiao Y, et al. Preliminary experience on treatment of infantile hemangioma with low-dose propranolol in China. Eur J Pediatr. 2013;172:653–59.
   PubMed Web of Science ®Google Scholar
• Xiao Q, Li Q, Zhang B, et al. Propranolol therapy of infantile hemangiomas: efficacy, adverse effects, and recurrence. Pediatr Surg Int. 2013;29:575–81.
   PubMed Web of Science ®Google Scholar
• Shupp CJ, Kleber JB, Günther P, et al. Propranolol therapy in 55 infants with infantile hemangioma: dosage, duration, adverse effects and outcome. Pediatr Dermatol. 2011;28:640–44.
   PubMed Web of Science ®Google Scholar
• Chu DH, Castelo-Soccio L, Wan J, et al. Retrospective analysis of beta-blocker instituted for treatment of hemangiomas (RABBIT study). Clin Pediatr (Phila). 2014;53:1084–90.
   PubMed Web of Science ®Google Scholar
• Filippi L, Cavallaro G, Fiorini P, et al. Propranolol concentrations after oral administration in term and preterm infants. J Matern Fetal Neonatal Med. 2013;26:833–40.
   PubMed Web of Science ®Google Scholar
• National high blood pressure education program working group on high blood pressure in children and adolescents. The fourth report on diagnosis, evaluation and treatment of high blood pressure in children and adolescents. Pediatrics. 2004;114:555–76.
   PubMed Web of Science ®Google Scholar
• Bernstein D, Evaluation of the cardiovascular system. In Kliegman RM, Stanton BF, St. Geme JW, et al., eds. Nelson Textbook of Pediatrics. Philadelphia: Elsevier Saunders, 2011. p 1532.
   Google Scholar
• Jacks SK, Kertesz NJ, Witman PM, et al. Experience with Holter monitoring during propranolol therapy for infantile hemangiomas. J Am Acad Dermatol. 2015;73:255–57.
   PubMed Web of Science ®Google Scholar
• Song H, Shi H, Zhang X, et al. Safety profile of a divided dose of propranolol for heart rate in children with infantile haemangioma during 16 weeks of treatment. Br J Dermatol. 2015;172:444–49.
   PubMed Web of Science ®Google Scholar
• Schneider M, Cremer H, Ruef P. A retrospective analysis of systemic propranolol for the treatment of complicated infantile haemangiomas. Acta Paediatr. 2014;103:977–83.
   PubMed Web of Science ®Google Scholar
• Stoschitzky K, Sakotnik A, Lercher P, et al. Influence of beta-blockers on melatonin release. Eur J Clin Pharmacol. 1999;55:111–15.
   PubMed Web of Science ®Google Scholar
• Lou Y, Peng WJ, Cao Y, et al. The effectiveness of propranolol in treating infantile haemangiomas: a meta-analysis including 35 studies. Br J Clin Pharmacol. 2014; 78:44–57.
   PubMed Web of Science ®Google Scholar
• Liu X, Tai M, Qin Z, et al. Clinical analysis for treatment of 1080 cases of infantile hemangiomas with oral propranolol. Zhonghua Yi Xue Za Zhi. 2014;94:1878–81.
   PubMedGoogle Scholar
• Szychta P, Stewart K, Anderson W. Treatment of infantile hemangiomas with propranolol: clinical guidelines. Plast Reconstr Surg. 2014;133:852–62.
   PubMed Web of Science ®Google Scholar
• Andersen IG, Rechnitzer C, Charabi B. Effectiveness of propanolol for treatment of infantile haemangioma. Dan Med J. 2014;61:A4776.
   PubMed Web of Science ®Google Scholar
• Tan CE, Itinteang T, Leadbitter P, et al. Low-dose propranolol regimen for infantile haemangioma. J Paediatr Child Health. 2014;51:419–24.
   PubMed Web of Science ®Google Scholar
• Léauté-Labrèze C, Hoeger P, Mazereeuw-Hautier J, et al. A randomized, controlled trial of oral propranolol in infantile hemangioma. N Engl J Med. 2015;372:735–46.
   PubMed Web of Science ®Google Scholar